Core Insights - The FDA provided constructive feedback on AEON Biopharma's analytical similarity strategy for ABP-450, a biosimilar to BOTOX, indicating support for the company's development approach [1][2][4] - AEON plans to request a BPD Type 2b meeting with the FDA in 2026 to discuss the next steps in the development program for ABP-450 [3] Company Overview - AEON Biopharma is focused on gaining full-label access to the U.S. therapeutic neurotoxin market, which exceeds $3.0 billion annually, through the development of ABP-450 [6] - ABP-450 is the same botulinum toxin complex currently marketed for cosmetic use as Jeuveau by Evolus, Inc. [6] - The product is already approved as a biosimilar in India, Mexico, and the Philippines, and AEON holds exclusive rights for therapeutic indications in the U.S., Canada, EU, UK, and other territories [6] Development Strategy - The FDA acknowledged the scientific challenges in characterizing the botulinum neurotoxin complex and provided feedback that supports AEON's analytical methodologies [2] - AEON aims to complete the majority of its analytical comparability program in 2026, which is crucial for advancing toward regulatory approval [2][4] - The analytical similarity is a critical phase in the biosimilar development process, potentially allowing the FDA to reduce the scope of required clinical studies if robust comparability is demonstrated [5]

AbbVie FY Conference Summary Company Overview - **Company**: AbbVie (NYSE: ABBV) - **Date of Conference**: March 03, 2026 - **Key Management Present**: - Scott Rents, Executive Vice President and CFO - Jeff Stewart, Executive Vice President and Chief Commercial Officer - Roopal Thakkar, Executive Vice President, R&D, and CSO Core Industry Insights - **Immunology Trials**: AbbVie is successfully conducting immunology trials, unlike some competitors facing high placebo rates. The company attributes its success to high efficacy levels of its assets, such as HUMIRA, SKYRIZI, and RINVOQ [2][3] - **Clinical Trial Strategy**: AbbVie employs rigorous patient and endpoint selection, real-time data monitoring, and training for trial sites to ensure successful outcomes [4][5][6] Key Product Developments - **RINVOQ**: Demonstrated a doubling of response rates compared to HUMIRA in rheumatoid arthritis trials, indicating strong efficacy [5] - **SKYRIZI**: New subcutaneous induction trial for Crohn's disease showed higher efficacy than the IV version, with a 60% endoscopic response in treatment-naive patients [6] - **Lutikizumab**: Undergoing phase 3 trials for hidradenitis suppurativa (HS) with a focus on stringent endpoints to control placebo responses [7][9] Market Potential - **Hidradenitis Suppurativa**: Identified as an under-penetrated market with significant growth potential, similar to inflammatory bowel disease (IBD) [13] - **Long-term Growth Outlook**: AbbVie projects a high single-digit CAGR from 2024 to 2029, with continued EPS expansion and a strong pipeline in immunology, oncology, and neuroscience [25][26] Pipeline and Future Strategies - **Immunology Pipeline**: Focus on B-cell depletion strategies and combination therapies to reset the standard of care in rheumatologic diseases [30][32] - **Neuroscience**: Anticipation of tavapadone approval, which is expected to complement existing therapies and capture significant market share [41] - **Oncology**: Development of antibody-drug conjugates (ADCs) for various cancers, with promising data from ongoing trials [34][38] Financial Outlook - **Investment in R&D**: AbbVie has increased R&D spending significantly, with plans to continue investing in pipeline development [26][28] - **BOTOX**: Continues to be a major asset with a strong market presence, particularly in aesthetics and therapeutics [50] Additional Insights - **Regulatory Strategy**: AbbVie is adapting to new trial policies to enhance efficiency and speed in clinical studies [14] - **Market Positioning**: The company is well-positioned to capitalize on its diverse portfolio and emerging therapies, with a focus on maintaining a competitive edge in the market [52][53] This summary encapsulates the key points discussed during the AbbVie FY Conference, highlighting the company's strategic focus, product developments, and market outlook.

Core Insights - AbbVie reported strong year-on-year revenue growth of 9.1%, reaching $15.78 billion, surpassing analyst estimates of $15.58 billion [6] - The growth was primarily driven by the immunology and neuroscience portfolios, particularly from products like Skyrizi and Rinvoq, alongside double-digit expansion in neuroscience products [1][6] - Despite exceeding Wall Street revenue and profit estimates, the market reacted negatively due to a significant drop in operating margin, which fell to 12.1% from 26.5% year-on-year [1][6] Financial Performance - Adjusted EPS was reported at $1.86, beating analyst estimates of $1.78 by 4.2% [6] - Adjusted EBITDA reached $5.07 billion, with a margin of 32.2%, exceeding analyst expectations of $4.86 billion [6] - Management lowered its full-year Adjusted EPS guidance to $10.63 at the midpoint, reflecting an 11.3% decrease [6] Market Dynamics - CEO Rob Michael highlighted the impact of challenging economic conditions on discretionary spending and emphasized the company's focus on core therapeutic areas [1] - Analysts raised concerns regarding evolving Pharmacy Benefit Manager (PBM) models and IRA price negotiations, with management asserting that these factors would not affect long-term guidance for key drugs [6] - Competitive dynamics in the IL-23 market were discussed, with indications that category expansion is benefiting Skyrizi [6] Aesthetics Segment - The aesthetics segment faced headwinds, with management acknowledging market softness for products like BOTOX and Juvederm [6] - Analysts inquired about the U.S. aesthetics market share, with management signaling that guidance is likely to be exceeded despite current challenges [6] Future Outlook - Management discussed the potential for recovery in the aesthetics market, pointing to consumer confidence and new product launches as leading indicators [6] - The company remains engaged with U.S. policymakers on issues related to access and innovation, indicating a proactive approach to navigating regulatory challenges [6]

Financial Data and Key Metrics Changes - Adjusted earnings per share for the third quarter were $1.86, exceeding guidance by $0.10 [5][31] - Total net revenues reached nearly $15.8 billion, reflecting high single-digit sales growth and beating expectations by approximately $300 million [5][31] - Adjusted gross margin was 83.9% of sales, with adjusted R&D expense at 14.3% and adjusted SG&A expense at 21.6% [31] - The adjusted operating margin ratio was 30.9% of sales, including a 17% unfavorable impact from acquired IPR&D expense [31] Business Line Data and Key Metrics Changes - Immunology revenues totaled approximately $7.9 billion, up 11.2% operationally, with SKYRIZI and RINVOQ showing combined sales growth of over 40% [11][12] - SKYRIZI global sales were $4.7 billion, reflecting operational growth of 46%, while RINVOQ revenues were nearly $2.2 billion, up 34.1% [11][12] - Oncology revenues were nearly $1.7 billion, remaining relatively flat year-over-year, with VENCLEXTA and newer products offsetting declines from IMBRUVICA [15][16] - Aesthetics sales were approximately $1.2 billion, down 4.2% operationally, with BOTOX and JUVÉDERM experiencing declines [16][17] - Neuroscience revenues exceeded $2.8 billion, up 19.6% operationally, driven by strong performance from UBRELVY, QULIPTA, and VRAYLAR [18][19] Market Data and Key Metrics Changes - The U.S. aesthetics market is currently facing challenges, with overall consumer sentiment low, impacting discretionary spending [17] - The IL-23 market is expanding rapidly, with SKYRIZI and RINVOQ maintaining strong positions despite competition from TREMFYA [49][50] - The Parkinson's disease treatment market is seeing significant uptake for VYALEV, with a competitive advantage over ONAPGO due to its 24-hour coverage [74][75] Company Strategy and Development Direction - AbbVie is focused on pipeline advancement across immunology, oncology, neuroscience, and aesthetics, with approximately 90 programs in development [7][8] - The company is investing heavily in R&D, anticipating $9 billion in adjusted R&D expense for 2025, to support numerous pipeline opportunities [7][9] - AbbVie is committed to external innovation, including recent acquisitions to enhance its psychiatry and immunology pipelines [8][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to adapt to changes in the PBM model and emphasized the importance of differentiated medicines [39][44] - The outlook for 2026 remains strong, with expectations for continued growth driven by the performance of SKYRIZI, RINVOQ, and the neuroscience portfolio [52][54] - Management highlighted the potential for significant growth in the neuroscience franchise, particularly with emerging products like tavapadon and VYALEV [61][78] Other Important Information - AbbVie announced a 5.5% increase in its quarterly cash dividend, reflecting a commitment to delivering a sustainable dividend [9][34] - The company has executed approximately 30 deals since the beginning of 2024, focusing on external innovation across key growth areas [35] Q&A Session Summary Question: Implications of the new PBM model and IRA price negotiations for VRAYLAR and LINZESS - Management emphasized the adaptability of AbbVie to changes in the PBM model and stated that the outcomes of IRA negotiations would not impact long-term guidance [39][44] Question: Competitive dynamics in the IL-23 market and outlook for 2026 - Management noted strong growth for SKYRIZI and RINVOQ, with confidence in maintaining competitive positions despite the entry of TREMFYA [49][50][54] Question: Long-term outlook for SKYRIZI and RINVOQ and market stress in aesthetics - Management indicated that the long-term guidance for SKYRIZI and RINVOQ may be exceeded, while also addressing challenges in the aesthetics market and plans for revitalization [59][63]

Financial Data and Key Metrics Changes - The company reported adjusted earnings per share of $2.46, which is $0.10 above the guidance midpoint [7][45] - Total net revenues exceeded $13.3 billion, reflecting robust growth of 9.8% on an operational basis, excluding a 1.4% unfavorable impact from foreign exchange [7][45] - The adjusted operating margin ratio was 42.3% of sales, including a 1.9% unfavorable impact from acquired IPR&D expense [46] Business Line Data and Key Metrics Changes - Immunology revenues were over $6.2 billion, with Skyrizi and Rinvoq contributing $5.1 billion in combined sales, reflecting growth of more than 65% [14][20] - Oncology revenues reached $1.6 billion, with Imbruvica global sales at $738 million (down 11.9%) and Venclexta global revenues at $665 million (up 12.3%) [20][21] - Aesthetics delivered global sales of $1.1 billion, down 10.2% on an operational basis, with BOTOX Cosmetic revenues at $556 million (down 10.7%) and Juvederm sales at $231 million (down 20%) [23][24] - Neuroscience revenues were approximately $2.3 billion, up 17% on an operational basis, with VRAYLAR global sales at $765 million (up 10.3%) [26][27] Market Data and Key Metrics Changes - The company anticipates total net revenues of approximately $59.7 billion for the year, an increase of $700 million from previous estimates [47] - Skyrizi global revenues are now expected to be $16.5 billion, an increase of $600 million, while Rinvoq global sales are projected at $8.2 billion, an increase of $300 million [48] - US Humira revenues are expected to decrease to $3.5 billion, reflecting higher erosion from biosimilar competition [49] Company Strategy and Development Direction - The company plans to invest over $10 billion in the US over the next decade to support volume growth and expansion into new areas such as obesity [10][54] - The company is focusing on advancing its internal pipeline and pursuing strategic acquisitions to drive growth, including the acquisition of Nimble Therapeutics [11][12] - The company aims for a high single-digit revenue CAGR through 2029, indicating a clear runway for growth [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong performance across therapeutic areas and raised full-year adjusted EPS guidance by $0.10 [9][45] - The company is preparing for potential impacts from sectoral tariffs but believes any related impact would be in line with peers due to its extensive US manufacturing presence [10][53] - Management highlighted the importance of a balanced approach to drug pricing and innovation, emphasizing the need for policies that support the biopharmaceutical industry [91][92] Other Important Information - The company is making significant progress in its pipeline, with several important data readouts and regulatory submissions expected throughout 2025 [44] - The company is also exploring the potential of its amylin analog for obesity treatment, with positive interim results from ongoing studies [42][43] Q&A Session Questions and Answers Question: Can you elaborate on the indications most attributable to the upside for Skyrizi and Rinvoq? - The company raised Skyrizi guidance by $600 million, with $200 million attributed to psoriasis and $400 million to IBD indications. Rinvoq was raised by $300 million across all approved indications [60][61] Question: How is the company thinking about the tail for Humira in light of erosion? - Management noted faster erosion from biosimilars and expects the Humira tail to step down further, with deeper visibility anticipated over the year [66] Question: Can you elaborate on potential mitigation strategies regarding tariffs? - The company plans to manage inventory, secure alternate sources of API, and look for cost efficiencies as potential mitigation strategies [75][76] Question: What are the expectations for the amylin program regarding dosing and efficacy? - The company is exploring higher doses in ongoing studies and anticipates larger sample sizes in future phases, with a focus on tolerability and weight loss efficacy [83][84] Question: How does the company view its manufacturing footprint in relation to US investments? - The company maintains a robust US manufacturing network and plans to invest over $10 billion to expand its production capabilities, ensuring supply assurance [123][126]

Financial Data and Key Metrics Changes - The company reported adjusted earnings per share of $2.46, which is $0.10 above the guidance midpoint [7][45] - Total net revenues exceeded $13.3 billion, reflecting robust growth of 9.8% on an operational basis, excluding a 1.4% unfavorable impact from foreign exchange [7][45] - The adjusted operating margin ratio was 42.3% of sales, including a 1.9% unfavorable impact from acquired IPR&D expense [46] Business Line Data and Key Metrics Changes - Immunology revenues were over $6.2 billion, with Skyrizi and Rinvoq contributing $5.1 billion in combined sales, reflecting growth of more than 65% [14][20] - Oncology revenues reached $1.6 billion, with Imbruvica global sales at $738 million (down 11.9%) and Venclexta global revenues at $665 million (up 12.3%) [20][21] - Aesthetics delivered global sales of $1.1 billion, down 10.2% on an operational basis, with BOTOX Cosmetic revenues at $556 million (down 10.7%) and Juvederm sales at $231 million (down 20%) [23][24] - Neuroscience revenues were approximately $2.3 billion, up 17% on an operational basis, with VRAYLAR global sales at $765 million (up 10.3%) [26][27] Market Data and Key Metrics Changes - The company anticipates total net revenues of approximately $59.7 billion for the year, an increase of $700 million from previous estimates [47] - Skyrizi global revenues are now expected to be $16.5 billion, an increase of $600 million, while Rinvoq global sales are projected at $8.2 billion, an increase of $300 million [48] - US Humira revenues are expected to decrease to $3.5 billion, reflecting higher erosion from biosimilar competition [49] Company Strategy and Development Direction - The company plans to invest over $10 billion in the US over the next decade to support volume growth and expansion into new areas such as obesity [10][54] - The company is focused on advancing its internal pipeline and pursuing strategic acquisitions to drive growth, including the acquisition of Nimble Therapeutics [11][12] - The company aims for a high single-digit revenue CAGR through 2029, indicating a clear runway for growth [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong performance across therapeutic areas and raised full-year adjusted EPS guidance by $0.10 [9][54] - The management acknowledged potential impacts from sectoral tariffs but believes any related effects would align with peers due to the company's extensive US manufacturing presence [10][53] - Management highlighted the importance of maintaining a competitive tax policy to encourage sustainable investment in US manufacturing [54][82] Other Important Information - The company is preparing for the global launch of giant cell arteritis for Rinvoq, which is expected to further enhance its rheumatology label [19] - The company is also making significant progress in its pipeline, with several important data readouts and regulatory submissions anticipated throughout 2025 [44] Q&A Session Summary Question: Insights on Skyrizi and Rinvoq's guidance increase - The increase in guidance for Skyrizi and Rinvoq is attributed to strong performance in IBD and rheumatology indications, with specific revenue increases detailed [60][61] Question: Thoughts on Humira's erosion - Management noted faster erosion due to biosimilar competition and expects further declines as the market matures [66] Question: Mitigation strategies regarding tariffs - The company plans to manage inventory and explore cost efficiencies to mitigate potential tariff impacts, while also expanding US manufacturing capacity [75][76] Question: Pricing strategy for BoNT/E - The pricing strategy for BoNT/E will be determined closer to launch, considering its shorter duration of action and potential market dynamics [106][107] Question: Future of emraclidine in schizophrenia - The company sees potential in emraclidine and plans to initiate a multiple ascending dose study to explore higher dosing options [120][121] Question: Manufacturing footprint and investment strategy - The company maintains a robust manufacturing network and plans to continue investing in US operations while ensuring supply chain resilience [123][126]

Core Points - AEON Biopharma has appointed Rob Bancroft as President and CEO, effective April 29, 2025, with Bancroft also joining the Board of Directors [1][2] - Bancroft has over 25 years of experience in the life sciences industry, including leadership roles at Revance Therapeutics and Allergan, where he was involved in the commercialization of BOTOX [2][3] - The company is focused on advancing its ABP-450 program along the 351(k) biosimilar regulatory pathway, aiming to bring ABP-450 to the U.S. market for all current and future BOTOX indications under a single FDA approval [2][3] Company Overview - AEON Biopharma is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) for various therapeutic indications, initially targeting the neurosciences market [3] - ABP-450 is the same botulinum toxin complex currently marketed for cosmetic use as Jeuveau by Evolus and is manufactured in compliance with cGMP [3] - The product has been approved as a biosimilar in Mexico and India, with AEON holding exclusive rights for therapeutic indications in the U.S., Canada, EU, UK, and other territories [3]

Leadership Transition - Marc Forth is stepping down as President and CEO of AEON Biopharma, effective April 4, 2025, to pursue another opportunity, but will remain on the Board of Directors [1] - Jost Fischer, the current Chairman of the Board, will serve as Interim CEO while the Board searches for a permanent replacement [1][2] Company Progress and Strategy - AEON is making progress along a 351(k) biosimilar regulatory pathway to potentially bring ABP-450 to the U.S. market for all of BOTOX's approved and future therapeutic indications under a single FDA approval [2] - The company anticipates a Biosimilar BPD Type 2a meeting with the FDA in the second half of 2025, with current cash balance expected to support this process [2] Product Development - AEON is focused on developing its proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, initially targeting the neurosciences market [3] - ABP-450 is the same botulinum toxin complex marketed for cosmetic use as Jeuveau by Evolus and is approved as a biosimilar in Mexico and India [3]